Immunopathogenesis of primary biliary cirrhosis: An old wives' tale

Immunity and Ageing

Volumn 8, Issue , 2011, Pages

  Smyk, Daniel S ^a   Rigopoulou, Eirini I ^b,c   Lleo, Ana ^d,e   Abeles, Robin D ^a   Mavropoulos, Athanasios ^a,c   Billinis, Charalambos ^b   Invernizzi, Pietro ^d,f   Bogdanos, Dimitrios P ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF THESSALY   (Greece)

^c INSTITUTE OF HUMAN PERFORMANCE AND REHABILITATION   (Greece)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ageing; Apoptosis; Autoantibody; Autoimmunity; Infection

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FAS ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; KI 67 ANTIGEN; MITOCHONDRION ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

AGING; AUTOIMMUNE DISEASE; CROSS REACTION; DNA FRAGMENTATION; ESCHERICHIA COLI; FEMALE; HUMAN; IMMUNE SYSTEM; LACTOBACILLUS DELBRUECKII; LIVER BIOPSY; LIVER TRANSPLANTATION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; URINARY TRACT INFECTION;

EID: 82455162799     PISSN: None     EISSN: 17424933     Source Type: Journal    
DOI: 10.1186/1742-4933-8-12     Document Type: Review

References (191)

1. Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. Semin Immunopathol 2009, 31:283-307.
2. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005, 353:1261-1273.
3. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology 2009, 50:291-308.
4. Selmi C, Invernizzi P, Keeffe EB, Coppel RL, Podda M, Rossaro L, Ansari AA, Gershwin ME. Epidemiology and pathogenesis of primary biliary cirrhosis. J Clin Gastroenterol 2004, 38:264-271.
5. Bogdanos DP, Baum H, Vergani D. Antimitochondrial and other autoantibodies. Clin Liver Dis 2003, 7:759-777, vi.
6. Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 2008, 14:3374-3387.
7. Bogdanos DP, Komorowski L. Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta 2011, 412:502-512.
8. Neuberger J. Primary biliary cirrhosis. Lancet 1997, 350:875-879.
9. Liaskos C, Bogdanos DP, Rigopoulou EI, Dalekos GN. Development of antimitochondrial antibodies in patients with autoimmune hepatitis: art of facts or an artifact?. J Gastroenterol Hepatol 2007, 22:454-455.
10. Liaskos C, Bogdanos DP, Davies ET, Dalekos GN. Diagnostic relevance of anti-filamentous actin antibodies in autoimmune hepatitis. J Clin Pathol 2007, 60:107-108.
11. Dalekos GN, Bogdanos DP, Neuberger J. Celiac disease-related autoantibodies in end-stage autoimmune liver diseases: what is the message?. Liver Int 2008, 28:426-428.
12. Bernal W, Meda F, Ma Y, Bogdanos DP, Vergani D. Disease-specific autoantibodies in patients with acute liver failure: the King's College London Experience. Hepatology 2008, 47:1096-1097. author reply 1097.
13. Bogdanos DP, Mieli-Vergani G, Vergani D. Autoantibodies and their antigens in autoimmune hepatitis. Semin Liver Dis 2009, 29:241-253.
14. Bogdanos DP, Mieli-Vergani G, Vergani D. Non-organ-specific autoantibodies in hepatitis C virus infection: do they matter?. Clin Infect Dis 2005, 40:508-510.
15. Bogdanos DP, Mieli-Vergani G, Vergani D. Non-organ-specific autoantibodies in children with chronic hepatitis C virus infection. Clin Infect Dis 2004, 38:1505. author reply 1505-1506.
16. Bogdanos DP, Gilbert D, Bianchi I, Leoni S, Mitry RR, Ma Y, Mieli-Vergani G, Vergani D. Antibodies to soluble liver antigen and alpha-enolase in patients with autoimmune hepatitis. J Autoimmune Dis 2004, 1:4.
17. Bogdanos DP, Bianchi I, Ma Y, Mitry RR, Mieli-Vergani G, Vergani D. Targets of antibodies to soluble liver antigen in patients with autoimmune hepatitis. Clin Chem 2004, 50:682-683. author reply 683-684.
18. Van Norstrand MD, Malinchoc M, Lindor KD, Therneau TM, Gershwin ME, Leung PS, Dickson ER, Homburger HA. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology 1997, 25:6-11.
19. Rigopoulou EI, Davies ET, Pares A, Zachou K, Liaskos C, Bogdanos DP, Rodes J, Dalekos GN, Vergani D. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005, 54:528-532.
20. Rigopoulou EI, Davies ET, Bogdanos DP, Liaskos C, Mytilinaiou M, Koukoulis GK, Dalekos GN, Vergani D. Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. Liver Int 2007, 27:1226-1231.
21. Rigopoulou EI, Bogdanos DP, Liaskos C, Koutsoumpas A, Baum H, Vergani D, Dalekos GN. Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. Clin Chim Acta 2007, 380:118-121.
22. Vergani D, Longhi MS, Bogdanos DP, Ma Y, Mieli-Vergani G. Autoimmune hepatitis. Semin Immunopathol 2009, 31:421-435.
23. Hannam S, Bogdanos DP, Davies ET, Hussain MJ, Portmann BC, Mieli-Vergani G, Vergani D. Neonatal liver disease associated with placental transfer of anti-mitochondrial antibodies. Autoimmunity 2002, 35:545-550.
24. Ma Y, Okamoto M, Thomas MG, Bogdanos DP, Lopes AR, Portmann B, Underhill J, Durr R, Mieli-Vergani G, Vergani D. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002, 35:658-664.
25. Bogdanos D, Pusl T, Rust C, Vergani D, Beuers U. Primary biliary cirrhosis following Lactobacillus vaccination for recurrent vaginitis. J Hepatol 2008, 49:466-473.
26. Dahnrich C, Pares A, Caballeria L, Rosemann A, Schlumberger W, Probst C, Mytilinaiou M, Bogdanos D, Vergani D, Stocker W, Komorowski L. New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. Clin Chem 2009, 55:978-985.
27. Gabeta S, Norman GL, Liaskos C, Papamichalis PA, Zografos T, Garagounis A, Rigopoulou EI, Dalekos GN. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J Clin Immunol 2007, 27:378-387.
28. Vergani D, Bogdanos DP. Positive markers in AMA-negative PBC. Am J Gastroenterol 2003, 98:241-243.
29. Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OF. Natural history of early primary biliary cirrhosis. Lancet 1996, 348:1399-1402.
30. Mitchison HC, Bassendine MF, Hendrick A, Bennett MK, Bird G, Watson AJ, James OF. Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis?. Hepatology 1986, 6:1279-1284.
31. Bogdanos DP, Liaskos C, Rigopoulou EI, Dalekos GN. Anti-mitochondrial antibodies in patients with systemic lupus erythematosus: revealing the unforeseen. Clin Chim Acta 2006, 373:183-184. author reply 185.
32. Bogdanos DP, Pares A, Rodes J, Vergani D. Primary biliary cirrhosis specific antinuclear antibodies in patients from Spain. The American journal of gastroenterology 2004, 99:763-764. author reply 765.
33. Gershwin ME, Mackay IR. Primary biliary cirrhosis: paradigm or paradox for autoimmunity. Gastroenterology 1991, 100:822-833.
34. Van de Water J, Ansari A, Prindiville T, Coppel RL, Ricalton N, Kotzin BL, Liu S, Roche TE, Krams SM, Munoz S, Gershwin ME. Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis. J Exp Med 1995, 181:723-733.
35. Harada K, Van de Water J, Leung PS, Coppel RL, Ansari A, Nakanuma Y, Gershwin ME. In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset. Hepatology 1997, 25:791-796.
36. Aoki CA, Roifman CM, Lian ZX, Bowlus CL, Norman GL, Shoenfeld Y, Mackay IR, Gershwin ME. IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun 2006, 27:50-53.
37. Dahlan Y, Smith L, Simmonds D, Jewell LD, Wanless I, Heathcote EJ, Bain VG. Pediatric-onset primary biliary cirrhosis. Gastroenterology 2003, 125:1476-1479.
38. Gregorio GV, Portmann B, Mowat AP, Vergani D, Mieli-Vergani G. A 12-year-old girl with antimitochondrial antibody-positive autoimmune hepatitis. J Hepatol 1997, 27:751-754.
39. Melegh B, Skuta G, Pajor L, Hegedus G, Sumegi B. Autoantibodies against subunits of pyruvate dehydrogenase and citrate synthase in a case of paediatric biliary cirrhosis. Gut 1998, 42:753-756.
40. Tsuda M, Torgerson TR, Selmi C, Gambineri E, Carneiro-Sampaio M, Mannurita SC, Leung PS, Norman GL, Gershwin ME. The spectrum of autoantibodies in IPEX syndrome is broad and includes anti-mitochondrial autoantibodies. J Autoimmun 2010, 35:265-268.
41. Zamfir O, Briaud I, Dubel L, Ballot E, Johanet C. Anti-pyruvate dehydrogenase autoantibodies in extrahepatic disorders. J Hepatol 1999, 31:964-965.
42. Longhi MS, Hussain MJ, Bogdanos DP, Quaglia A, Mieli-Vergani G, Ma Y, Vergani D. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 2007, 46:472-484.
43. Ma Y, Bogdanos DP, Hussain MJ, Underhill J, Bansal S, Longhi MS, Cheeseman P, Mieli-Vergani G, Vergani D. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006, 130:868-882.
44. Longhi MS, Ma Y, Mitry RR, Bogdanos DP, Heneghan M, Cheeseman P, Mieli-Vergani G, Vergani D. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun 2005, 25:63-71.
45. Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 2004, 41:31-37.
46. Shimoda S, Harada K, Niiro H, Yoshizumi T, Soejima Y, Taketomi A, Maehara Y, Tsuneyama K, Nakamura M, Komori A, et al. Biliary epithelial cells and primary biliary cirrhosis: the role of liver-infiltrating mononuclear cells. Hepatology 2008, 47:958-965.
47. Selmi C, Gershwin ME. Bacteria and human autoimmunity: the case of primary biliary cirrhosis. Curr Opin Rheumatol 2004, 16:406-410.
48. Selmi C, Mackay IR, Gershwin ME. The immunological milieu of the liver. Semin Liver Dis 2007, 27:129-139.
49. Selmi C, Meda F, Kasangian A, Invernizzi P, Tian Z, Lian Z, Podda M, Gershwin ME. Experimental evidence on the immunopathogenesis of primary biliary cirrhosis. Cell Mol Immunol 2010, 7:1-10.
50. Hirschfield GM, Invernizzi P. Progress in the genetics of primary biliary cirrhosis. Semin Liver Dis 2011, 31:147-156.
51. Hirschfield GM, Heathcote EJ, Gershwin ME. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 2010, 139:1481-1496.
52. Amano K, Leung PS, Xu Q, Marik J, Quan C, Kurth MJ, Nantz MH, Ansari AA, Lam KS, Zeniya M, et al. Xenobiotic-induced loss of tolerance in rabbits to the mitochondrial autoantigen of primary biliary cirrhosis is reversible. J Immunol 2004, 172:6444-6452.
53. Van de Water J, Turchany J, Leung PS, Lake J, Munoz S, Surh CD, Coppel R, Ansari A, Nakanuma Y, Gershwin ME. Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest 1993, 91:2653-2664.
54. Van de Water J, Ishibashi H, Coppel RL, Gershwin ME. Molecular mimicry and primary biliary cirrhosis: premises not promises. Hepatology 2001, 33:771-775.
55. Koutsoumpas A, Polymeros D, Tsiamoulos Z, Smyk D, Karamanolis G, Triantafyllou K, Rigopoulou EI, Forbes A, Vergani D, Bogdanos DP, Ladas SD. Peculiar antibody reactivity to human connexin 37 and its microbial mimics in patients with Crohn's disease. J Crohns Colitis 2011, 5:101-109.
56. Polymeros D, Bogdanos DP, Day R, Arioli D, Vergani D, Forbes A. Does cross-reactivity between mycobacterium avium paratuberculosis and human intestinal antigens characterize Crohn's disease?. Gastroenterology 2006, 131:85-96.
57. Koutsoumpas A, Mytilinaiou M, Polymeros D, Dalekos GN, Bogdanos DP. Anti-Helicobacter pylori antibody responses specific for VacA do not trigger primary biliary cirrhosis-specific antimitochondrial antibodies. Eur J Gastroenterol Hepatol 2009, 21:1220.
58. Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 2001, 21:225-232.
59. Bogdanos DP, Mieli-Vergani G, Vergani D. Virus, liver and autoimmunity. Dig Liver Dis 2000, 32:440-446.
60. Wen L, Ma Y, Bogdanos DP, Wong FS, Demaine A, Mieli-Vergani G, Vergani D. Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity. Curr Mol Med 2001, 1:379-389.
61. Corpechot C, Chretien Y, Chazouilleres O, Poupon R. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. Journal of hepatology 2010, 53:162-169.
62. Gershwin ME, Mackay IR. The causes of primary biliary cirrhosis: Convenient and inconvenient truths. Hepatology 2008, 47:737-745.
63. Parikh-Patel A, Gold EB, Worman H, Krivy KE, Gershwin ME. Risk factors for primary biliary cirrhosis in a cohort of patients from the united states. Hepatology 2001, 33:16-21.
64. Prince MI, Ducker SJ, James OF. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut 2010, 59:508-512.
65. Smyk D, Mytilinaiou MG, Rigopoulou EI, Bogdanos DP. PBC triggers in water reservoirs, coal mining areas and waste disposal sites: from Newcastle to New York. Dis Markers 2010, 29:337-344.
66. Triger DR. Primary biliary cirrhosis: an epidemiological study. Br Med J 1980, 281:772-775.
67. Amano K, Leung PS, Rieger R, Quan C, Wang X, Marik J, Suen YF, Kurth MJ, Nantz MH, Ansari AA, et al. Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. J Immunol 2005, 174:5874-5883.
68. Kouroumalis E. Environmental agents involved in the cause of primary biliary cirrhosis. Dis Markers 2010, 29:329-336.
69. Smyk D, Cholongitas E, Kriese S, Rigopoulou EI, Bogdanos DP. Primary biliary cirrhosis: family stories. Autoimmune Dis 2011, 2011:189585.
70. Smyk D, Rigopoulou EI, Baum H, Burroughs AK, Vergani D, Bogdanos DP. Autoimmunity and Environment: Am I at risk?. Clin Rev Allergy Immunol 2011,
71. Smyk DS, Bogdanos DP, Kriese S, Billinis C, Burroughs AK, Rigopoulou EI. Urinary tract infection as a risk factor for autoimmune liver disease: From bench to bedside. Clin Res Hepatol Gastroenterol 2011,
72. Siegel SM, Selmi C, Dottorini L, Antelmi M, Zuin M, Lanfredini M, Gershwin ME. Late-onset autoimmunity: the paradigm of primary biliary cirrhosis--a mini-review. Gerontology 2008, 54:193-201.
73. Hakim FT, Flomerfelt FA, Boyiadzis M, Gress RE. Aging, immunity and cancer. Curr Opin Immunol 2004, 16:151-156.
74. Prelog M. Aging of the immune system: a risk factor for autoimmunity?. Autoimmun Rev 2006, 5:136-139.
75. Fulop T, Larbi A, Dupuis G, Pawelec G. Ageing, autoimmunity and arthritis: Perturbations of TCR signal transduction pathways with ageing - a biochemical paradigm for the ageing immune system. Arthritis Res Ther 2003, 5:290-302.
76. Vallejo AN. CD28 extinction in human T cells: altered functions and the program of T-cell senescence. Immunol Rev 2005, 205:158-169.
77. Vallejo AN. Immunological hurdles of ageing: Indispensable research of the human model. Ageing Res Rev 2011,
78. Weng NP, Akbar AN, Goronzy J. CD28(-) T cells: their role in the age-associated decline of immune function. Trends Immunol 2009, 30:306-312.
79. Azuma M, Phillips JH, Lanier LL. CD28 co-stimulation of T-cell-mediated cytotoxicity. Int J Cancer Suppl 1992, 7:33-35.
80. Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O'Fallon WM, Weyand CM. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol 2001, 75:12182-12187.
81. Konya C, Goronzy JJ, Weyand CM. Treating autoimmune disease by targeting CD8(+) T suppressor cells. Expert Opin Biol Ther 2009, 9:951-965.
82. Bogdanos DP, Baum H, Butler P, Rigopoulou EI, Davies ET, Ma Y, Burroughs AK, Vergani D. Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection. Dig Liver Dis 2003, 35:801-805.
83. Bogdanos DP, Baum H, Grasso A, Okamoto M, Butler P, Ma Y, Rigopoulou E, Montalto P, Davies ET, Burroughs AK, Vergani D. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol 2004, 40:31-39.
84. Bogdanos DP, Baum H, Gunsar F, Arioli D, Polymeros D, Ma Y, Burroughs AK, Vergani D. Extensive homology between the major immunodominant mitochondrial antigen in primary biliary cirrhosis and Helicobacter pylori does not lead to immunological cross-reactivity. Scand J Gastroenterol 2004, 39:981-987.
85. Bogdanos DP, Baum H, Sharma UC, Grasso A, Ma Y, Burroughs AK, Vergani D. Antibodies against homologous microbial caseinolytic proteases P characterise primary biliary cirrhosis. J Hepatol 2002, 36:14-21.
86. Bogdanos DP, Baum H, Vergani D, Burroughs AK. The role of E. coli infection in the pathogenesis of primary biliary cirrhosis. Dis Markers 2010, 29:301-311.
87. Bogdanos DP, Vergani D. Origin of cross-reactive autoimmunity in primary biliary cirrhosis. Liver Int 2006, 26:633-635.
88. Bogdanos DP, Vergani D. Bacteria and primary biliary cirrhosis. Clin Rev Allergy Immunol 2009, 36:30-39.
89. Burroughs AK, Rosenstein IJ, Epstein O, Hamilton-Miller JM, Brumfitt W, Sherlock S. Bacteriuria and primary biliary cirrhosis. Gut 1984, 25:133-137.
90. Selmi C, Gershwin ME. The role of environmental factors in primary biliary cirrhosis. Trends Immunol 2009, 30:415-420.
91. Shimoda S, Nakamura M, Shigematsu H, Tanimoto H, Gushima T, Gershwin ME, Ishibashi H. Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis. Hepatology 2000, 31:1212-1216.
92. Bernuzzi F, Fenoglio D, Battaglia F, Fravega M, Gershwin ME, Indiveri F, Ansari AA, Podda M, Invernizzi P, Filaci G. Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. J Autoimmun 2010, 35:176-180.
93. Georgin-Lavialle S, Aouba A, Mouthon L, Londono-Vallejo JA, Lepelletier Y, Gabet AS, Hermine O. The telomere/telomerase system in autoimmune and systemic immune-mediated diseases. Autoimmun Rev 2010, 9:646-651.
94. Artlett CM, Black CM, Briggs DC, Stevens CO, Welsh KI. Telomere reduction in scleroderma patients: a possible cause for chromosomal instability. Br J Rheumatol 1996, 35:732-737.
95. Beier F, Balabanov S, Amberger CC, Hartmann U, Manger K, Dietz K, Kotter I, Brummendorf TH. Telomere length analysis in monocytes and lymphocytes from patients with systemic lupus erythematosus using multi-color flow-FISH. Lupus 2007, 16:955-962.
96. Colmegna I, Diaz-Borjon A, Fujii H, Schaefer L, Goronzy JJ, Weyand CM. Defective proliferative capacity and accelerated telomeric loss of hematopoietic progenitor cells in rheumatoid arthritis. Arthritis Rheum 2008, 58:990-1000.
97. Honda M, Mengesha E, Albano S, Nichols WS, Wallace DJ, Metzger A, Klinenberg JR, Linker-Israeli M. Telomere shortening and decreased replicative potential, contrasted by continued proliferation of telomerase-positive CD8+CD28(lo) T cells in patients with systemic lupus erythematosus. Clin Immunol 2001, 99:211-221.
98. Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci USA 2000, 97:9203-9208.
99. Kurosaka D, Yasuda J, Yoshida K, Yokoyama T, Ozawa Y, Obayashi Y, Kingetsu I, Saito S, Yamada A. Telomerase activity and telomere length of peripheral blood mononuclear cells in SLE patients. Lupus 2003, 12:591-599.
100. Kurosaka D, Yasuda J, Yoshida K, Yoneda A, Yasuda C, Kingetsu I, Toyokawa Y, Yokoyama T, Saito S, Yamada A. Abnormal telomerase activity and telomere length in T and B cells from patients with systemic lupus erythematosus. J Rheumatol 2006, 33:1102-1107.
101. MacIntyre A, Brouilette SW, Lamb K, Radhakrishnan K, McGlynn L, Chee MM, Parkinson EK, Freeman D, Madhok R, Shiels PG. Association of increased telomere lengths in limited scleroderma, with a lack of age-related telomere erosion. Ann Rheum Dis 2008, 67:1780-1782.
102. Schonland SO, Lopez C, Widmann T, Zimmer J, Bryl E, Goronzy JJ, Weyand CM. Premature telomeric loss in rheumatoid arthritis is genetically determined and involves both myeloid and lymphoid cell lineages. Proc Natl Acad Sci USA 2003, 100:13471-13476.
103. Wu CH, Hsieh SC, Li KJ, Lu MC, Yu CL. Premature telomere shortening in polymorphonuclear neutrophils from patients with systemic lupus erythematosus is related to the lupus disease activity. Lupus 2007, 16:265-272.
104. Sasaki M, Ikeda H, Yamaguchi J, Nakada S, Nakanuma Y. Telomere shortening in the damaged small bile ducts in primary biliary cirrhosis reflects ongoing cellular senescence. Hepatology 2008, 48:186-195.
105. Katayama Y, Kohriyama K. Telomerase activity in peripheral blood mononuclear cells of systemic connective tissue diseases. J Rheumatol 2001, 28:288-291.
106. Tarhan F, Vural F, Kosova B, Aksu K, Cogulu O, Keser G, Gunduz C, Tombuloglu M, Oder G, Karaca E, Doganavsargil E. Telomerase activity in connective tissue diseases: elevated in rheumatoid arthritis, but markedly decreased in systemic sclerosis. Rheumatol Int 2008, 28:579-583.
107. Prelog M, Schwarzenbrunner N, Sailer-Hock M, Kern H, Klein-Franke A, Ausserlechner MJ, Koppelstaetter C, Brunner A, Duftner C, Dejaco C, et al. Premature aging of the immune system in children with juvenile idiopathic arthritis. Arthritis Rheum 2008, 58:2153-2162.
108. Kurosaka D, Yasuda J, Kingetsu I, Yasuda C, Yoshida K, Toyokawa Y, Yokoyama T, Yamada A. Two cases of adult Still's disease with abnormally high level of telomerase activity in peripheral blood mononuclear cells. Mod Rheumatol 2004, 14:394-398.
109. Vogt S, Iking-Konert C, Hug F, Andrassy K, Hansch GM. Shortening of telomeres: Evidence for replicative senescence of T cells derived from patients with Wegener's granulomatosis. Kidney Int 2003, 63:2144-2151.
110. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007, 130:223-233.
111. Sasaki M, Nakanuma Y. Biliary epithelial apoptosis, autophagy, and senescence in primary biliary cirrhosis. Hepat Res Treat 2010, 2010:205128.
112. Sasaki M, Ikeda H, Haga H, Manabe T, Nakanuma Y. Frequent cellular senescence in small bile ducts in primary biliary cirrhosis: a possible role in bile duct loss. J Pathol 2005, 205:451-459.
113. Sasaki M, Ikeda H, Nakanuma Y. Activation of ATM signaling pathway is involved in oxidative stress-induced expression of mito-inhibitory p21WAF1/Cip1 in chronic non-suppurative destructive cholangitis in primary biliary cirrhosis: an immunohistochemical study. J Autoimmun 2008, 31:73-78.
114. Sasaki M, Ikeda H, Sato Y, Nakanuma Y. Decreased expression of Bmi1 is closely associated with cellular senescence in small bile ducts in primary biliary cirrhosis. Am J Pathol 2006, 169:831-845.
115. Alvaro D, Mancino MG, Glaser S, Gaudio E, Marzioni M, Francis H, Alpini G. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology 2007, 132:415-431.
116. Isse K, Harada K, Zen Y, Kamihira T, Shimoda S, Harada M, Nakanuma Y. Fractalkine and CX3CR1 are involved in the recruitment of intraepithelial lymphocytes of intrahepatic bile ducts. Hepatology 2005, 41:506-516.
117. Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. Modulation of the microenvironment by senescent biliary epithelial cells may be involved in the pathogenesis of primary biliary cirrhosis. J Hepatol 2010, 53:318-325.
118. Tsuneyama K, Harada K, Yasoshima M, Hiramatsu K, Mackay CR, Mackay IR, Gershwin ME, Nakanuma Y. Monocyte chemotactic protein-1, -2, and -3 are distinctively expressed in portal tracts and granulomata in primary biliary cirrhosis: implications for pathogenesis. J Pathol 2001, 193:102-109.
119. Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. Autophagy mediates the process of cellular senescence characterizing bile duct damages in primary biliary cirrhosis. Lab Invest 2010, 90:835-843.
120. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
121. Mizushima N. Autophagy: process and function. Genes Dev 2007, 21:2861-2873.
122. White E, Lowe SW. Eating to exit: autophagy-enabled senescence revealed. Genes Dev 2009, 23:784-787.
123. Yin XM, Ding WX, Gao W. Autophagy in the liver. Hepatology 2008, 47:1773-1785.
124. Munoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 2010, 6:280-289.
125. Schulze C, Munoz LE, Franz S, Sarter K, Chaurio RA, Gaipl US, Herrmann M. Clearance deficiency--a potential link between infections and autoimmunity. Autoimmun Rev 2008, 8:5-8.
126. Lauber K, Bohn E, Krober SM, Xiao YJ, Blumenthal SG, Lindemann RK, Marini P, Wiedig C, Zobywalski A, Baksh S, et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 2003, 113:717-730.
127. Savill J. Apoptosis in resolution of inflammation. J Leukoc Biol 1997, 61:375-380.
128. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997, 390:350-351.
129. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998, 41:1241-1250.
130. Rosen A, Casciola-Rosen L. Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ 1999, 6:6-12.
131. Svensson B. Occurrence of deficient monocyte yeast cell phagocytosis in presence of rheumatic sera. Scand J Rheumatol Suppl 1980, 31:21-27.
132. Allina J, Hu B, Sullivan DM, Fiel MI, Thung SN, Bronk SF, Huebert RC, van de Water J, LaRusso NF, Gershwin ME, et al. T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun 2006, 27:232-241.
133. Heyder P, Bekeredjian-Ding I, Parcina M, Blank N, Ho AD, Herrmann M, Lorenz HM, Heeg K, Schiller M. Purified apoptotic bodies stimulate plasmacytoid dendritic cells to produce IFN-alpha. Autoimmunity 2007, 40:331-332.
134. Lleo A, Bowlus CL, Yang GX, Invernizzi P, Podda M, Van de Water J, Ansari AA, Coppel RL, Worman HJ, Gores GJ, Gershwin ME. Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology 2010, 52:987-998.
135. Lleo A, Selmi C, Invernizzi P, Podda M, Coppel RL, Mackay IR, Gores GJ, Ansari AA, Van de Water J, Gershwin ME. Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology 2009, 49:871-879.
136. Odin JA, Huebert RC, Casciola-Rosen L, LaRusso NF, Rosen A. Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. J Clin Invest 2001, 108:223-232.
137. Radic M, Marion T, Monestier M. Nucleosomes are exposed at the cell surface in apoptosis. J Immunol 2004, 172:6692-6700.
138. Schiller M, Bekeredjian-Ding I, Heyder P, Blank N, Ho AD, Lorenz HM. Autoantigens are translocated into small apoptotic bodies during early stages of apoptosis. Cell Death Differ 2008, 15:183-191.
139. Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, Neuhuber WL, Kirchner T, Kalden JR, Herrmann M. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002, 46:191-201.
140. Hepburn AL, Lampert IA, Boyle JJ, Horncastle D, Ng WF, Layton M, Vyse TJ, Botto M, Mason JC. In vivo evidence for apoptosis in the bone marrow in systemic lupus erythematosus. Ann Rheum Dis 2007, 66:1106-1109.
141. Kuhn A, Herrmann M, Kleber S, Beckmann-Welle M, Fehsel K, Martin-Villalba A, Lehmann P, Ruzicka T, Krammer PH, Kolb-Bachofen V. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum 2006, 54:939-950.
142. Lorenz HM, Grunke M, Hieronymus T, Herrmann M, Kuhnel A, Manger B, Kalden JR. In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum 1997, 40:306-317.
143. Koga H, Sakisaka S, Ohishi M, Sata M, Tanikawa K. Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology 1997, 25:1077-1084.
144. Kuroki T, Seki S, Kawakita N, Nakatani K, Hisa T, Kitada T, Sakaguchi H. Expression of antigens related to apoptosis and cell proliferation in chronic nonsuppurative destructive cholangitis in primary biliary cirrhosis. Virchows Arch 1996, 429:119-129.
145. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, Lindor KD, Kaplan MM, Vierling JM. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005, 42:1194-1202.
146. Butler P, Valle F, Hamilton-Miller JM, Brumfitt W, Baum H, Burroughs AK. M2 mitochondrial antibodies and urinary rough mutant bacteria in patients with primary biliary cirrhosis and in patients with recurrent bacteriuria. J Hepatol 1993, 17:408-414.
147. Varyani FK, West J, Card TR. An increased risk of Urinary Tract Infection precedes development of Primary Biliary Cirrhosis. BMC Gastroenterol 2011, 11:95.
148. Matthews SJ, Lancaster JW. Urinary Tract Infections in the Elderly Population. Am J Geriatr Pharmacother 2011,
149. Hopf U, Moller B, Stemerowicz R, Lobeck H, Rodloff A, Freudenberg M, Galanos C, Huhn D. Relation between Escherichia coli R(rough)-forms in gut, lipid A in liver, and primary biliary cirrhosis. Lancet 1989, 2:1419-1422.
150. Vergani D, Bogdanos DP, Baum H. Unusual suspects in primary biliary cirrhosis. Hepatology 2004, 39:38-41.
151. Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis 2002, 6:727-737.
152. Ma Y, Thomas MG, Okamoto M, Bogdanos DP, Nagl S, Kerkar N, Lopes AR, Muratori L, Lenzi M, Bianchi FB, et al. Key residues of a major cytochrome P4502D6 epitope are located on the surface of the molecule. J Immunol 2002, 169:277-285.
153. Gregorio GV, Choudhuri K, Ma Y, Pensati P, Iorio R, Grant P, Garson J, Bogdanos DP, Vegnente A, Mieli-Vergani G, Vergani D. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol 2003, 133:404-413.
154. Gregorio GV, Choudhuri K, Ma Y, Vegnente A, Mieli-Vergani G, Vergani D. Mimicry between the hepatitis B virus DNA polymerase and the antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis B virus infection. J Immunol 1999, 162:1802-1810.
155. Kerkar N, Choudhuri K, Ma Y, Mahmoud A, Bogdanos DP, Muratori L, Bianchi F, Williams R, Mieli-Vergani G, Vergani D. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 2003, 170:1481-1489.
156. Bogdanos DP, Muratori L, Bianchi FB, Vergani D. Hepatitis C virus and autoimmunity. Hepatology 2000, 31:1380.
157. Bogdanos DP, Dalekos GN. Enzymes as target antigens of liver-specific autoimmunity: the case of cytochromes P450s. Curr Med Chem 2008, 15:2285-2292.
158. Bogdanos DP, McFarlane IG. Cytochrome P450 2A6 meets P450 2D6: an enigma of viral infections and autoimmunity. J Hepatol 2003, 39:860-863.
159. Bogdanos DP, Lenzi M, Okamoto M, Rigopoulou EI, Muratori P, Ma Y, Muratori L, Tsantoulas D, Mieli- Vergani G, Bianchi FB, Vergani D. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. Int J Immunopathol Pharmacol 2004, 17:83-92.
160. Muratori L, Bogdanos DP, Muratori P, Lenzi M, Granito A, Ma Y, Mieli-Vergani G, Bianchi FB, Vergani D. Susceptibility to thyroid disorders in hepatitis C. Clin Gastroenterol Hepatol 2005, 3:595-603.
161. Baum H. Nature of the mitochondrial antigens of primary biliary cirrhosis and their possible relationships to the etiology of the disease. Semin Liver Dis 1989, 9:117-123.
162. Butler P, Hamilton-Miller J, Baum H, Burroughs AK. Detection of M2 antibodies in patients with recurrent urinary tract infection using an ELISA and purified PBC specific antigens. Evidence for a molecular mimicry mechanism in the pathogenesis of primary biliary cirrhosis?. Biochem Mol Biol Int 1995, 35:473-485.
163. Baum H, Bogdanos DP, Vergani D. Antibodies to Clp protease in primary biliary cirrhosis: possible role of a mimicking T-cell epitope. J Hepatol 2001, 34:785-787.
164. Mayo I, Arizti P, Pares A, Oliva J, Doforno RA, de Sagarra MR, Rodes J, Castano JG. Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis. J Hepatol 2000, 33:528-536.
165. Shimoda S, Nakamura M, Ishibashi H, Hayashida K, Niho Y. HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med 1995, 181:1835-1845.
166. Shimoda S, Van de Water J, Ansari A, Nakamura M, Ishibashi H, Coppel RL, Lake J, Keeffe EB, Roche TE, Gershwin ME. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest 1998, 102:1831-1840.
167. Bogdanos DP, Baum H, Okamoto M, Montalto P, Sharma UC, Rigopoulou EI, Vlachogiannakos J, Ma Y, Burroughs AK, Vergani D. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology 2005, 42:458-465.
168. Bernier M, Njomnang Soh P, Lochet A, Prots L, Felice R, Senescau A, Fabre R, Philippon A. [Lactobacillus delbrueckii: Probable agent of urinary tract infections in very old women.]. Pathol Biol (Paris) 2010,
169. Darbro BW, Petroelje BK, Doern GV. Lactobacillus delbrueckii as the cause of urinary tract infection. J Clin Microbiol 2009, 47:275-277.
170. Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, Leung PS, Kenny TP, Van De Water J, Nantz MH, et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 2003, 38:1250-1257.
171. Mattner J, Savage PB, Leung P, Oertelt SS, Wang V, Trivedi O, Scanlon ST, Pendem K, Teyton L, Hart J, et al. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe 2008, 3:304-315.
172. Stellon AJ, Williams R. Increased incidence of menstrual abnormalities and hysterectomy preceding primary biliary cirrhosis. Br Med J 1986, 293:297-298.
173. Parikh-Patel A, Gold E, Utts J, Gershwin ME. The association between gravidity and primary biliary cirrhosis. Ann Epidemiol 2002, 12:264-272.
174. Alvaro D, Invernizzi P, Onori P, Franchitto A, De Santis A, Crosignani A, Sferra R, Ginanni-Corradini S, Mancino MG, Maggioni M, et al. Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis. J Hepatol 2004, 41:905-912.
175. Alvaro D, Mancino MG, Onori P, Franchitto A, Alpini G, Francis H, Glaser S, Gaudio E. Estrogens and the pathophysiology of the biliary tree. World J Gastroenterol 2006, 12:3537-3545.
176. Alvaro D, Onori P, Metalli VD, Svegliati-Baroni G, Folli F, Franchitto A, Alpini G, Mancino MG, Attili AF, Gaudio E. Intracellular pathways mediating estrogen-induced cholangiocyte proliferation in the rat. Hepatology 2002, 36:297-304.
177. Guattery JM, Faloon WW. Effect of estradiol upon serum enzymes in primary biliary cirrhosis. Hepatology 1987, 7:737-742.
178. Mason AL. The evidence supports a viral aetiology for primary biliary cirrhosis. J Hepatol 2011, 54:1312-1314.
179. Mason AL, Zhang G. Linking human beta retrovirus infection with primary biliary cirrhosis. Gastroenterol Clin Biol 2010, 34:359-366.
180. Montano-Loza AJ, Wasilenko S, Bintner J, Mason AL. Cyclosporine A inhibits in vitro replication of betaretrovirus associated with primary biliary cirrhosis. Liver Int 2010, 30:871-877.
181. Mason AL, Xu L, Guo L, Munoz S, Jaspan JB, Bryer-Ash M, Cao Y, Sander DM, Shoenfeld Y, Ahmed A, et al. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 1998, 351:1620-1624.
182. Mason A, Xu L, Shen Z, Fodera B, Joplin R, Neuberger J, O'Donnell B. Patients with primary biliary cirrhosis make anti-viral and anti-mitochondrial antibodies to mouse mammary tumor virus. Gastroenterology 2004, 127:1863-1864. author reply 1864-1865.
183. Xu L, Shen Z, Guo L, Fodera B, Keogh A, Joplin R, O'Donnell B, Aitken J, Carman W, Neuberger J, Mason A. Does a betaretrovirus infection trigger primary biliary cirrhosis?. Proc Natl Acad Sci USA 2003, 100:8454-8459.
184. Selmi C, Ross SR, Ansari AA, Invernizzi P, Podda M, Coppel RL, Gershwin ME. Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology 2004, 127:493-501.
185. Johal H, Scott GM, Jones R, Camaris C, Riordan S, Rawlinson WD. Mouse mammary tumour virus-like virus (MMTV-LV) is present within the liver in a wide range of hepatic disorders and unrelated to nuclear p53 expression or hepatocarcinogenesis. J Hepatol 2009, 50:548-554.
186. Sadamoto T, Joplin R, Keogh A, Mason A, Carman W, Neuberger J. Expression of pyruvate-dehydrogenase complex PDC-E2 on biliary epithelial cells induced by lymph nodes from primary biliary cirrhosis. Lancet 1998, 352:1595-1596.
187. Wasilenko ST, Mason GE, Mason AL. Primary biliary cirrhosis, bacteria and molecular mimicry: what's the molecule and where's the mimic?. Liver Int 2009, 29:779-782.
188. Mason AL, Farr GH, Xu L, Hubscher SG, Neuberger JM. Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. Am J Gastroenterol 2004, 99:2348-2355.
189. Mason AL, Wasilenko ST. Other potential medical therapies: the use of antiviral agents to investigate and treat primary ciliary cirrhosis. Clin Liver Dis 2008, 12:445-460. xi.
190. Mason AL, Lindor KD, Bacon BR, Vincent C, Neuberger JM, Wasilenko ST. Clinical Trial: Randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther 2008,
191. Selmi C. The evidence does not support a viral etiology for primary biliary cirrhosis. J Hepatol 2011, 54:1315-1316.